India, Switzerland Strengthen Collaboration in Biotech & Pharma Innovation

The collaboration expands joint work in vaccine development, biologics, precision therapeutics, and clinical research, while promoting regulatory harmonization to speed the transition of innovations into market-ready therapies.

India and Switzerland have agreed to expand cooperation across biotechnology, pharmaceuticals, and advanced research, marking a renewed push to strengthen bilateral innovation and regulatory alignment between the two nations.

The agreement follows high-level discussions centered on accelerating drug development, joint scientific research, and innovation-driven manufacturing.

Officials from both countries highlighted that the collaboration expands on ongoing efforts in biotechnology, including vaccine development, biologics, precision medicine, and clinical research ecosystems.

The engagement also supports knowledge exchange between regulatory bodies to streamline approval pathways and enable faster translation of research into market-ready therapies.

During the discussions, senior representatives emphasized the strategic value of building long-term R&D partnerships that support global health priorities.

Dr Mansukh Mandaviya, Union Minister of Health & Family Welfare, Government of India, noted, “Our partnership with Switzerland enables a stronger innovation ecosystem, opening pathways for collaborative research, next-generation therapeutics and a more harmonized regulatory environment.”

Delegates from Switzerland underlined the importance of deepening ties with India’s rapidly expanding pharma and biotech ecosystem, which provides scale, scientific capacity, and a large innovation pipeline.

Flavia Kleiner, Senior Official, Swiss State Secretariat for Economic Affairs (SECO), mentioned, “India’s biotech landscape is evolving at remarkable speed. Strengthening our collaboration creates opportunities for joint development across diagnostics, biologics and cutting-edge therapeutic platforms.”

The bilateral dialogue also focused on facilitating industry-academia partnerships, enabling technology transfer, promoting start-up engagement, and expanding manufacturing collaboration for high-value pharma products.

Regulatory agencies from both nations discussed mechanisms for cooperation in safety evaluation, quality standards, and scientific exchange to support emerging areas such as cell and gene therapies, digital health-integrated therapeutics, and complex generics.

Officials noted that the partnership enhances global supply-chain resilience by encouraging co-development and co-manufacturing models between Indian and Swiss companies within the pharmaceutical and biotech domains.

Stay tuned for more such updates on Digital Health News